Faculty Collaboration Database

No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant. Clin Transplant 2018 May;32(5):e13246

Date

03/27/2018

Pubmed ID

29577449

DOI

10.1111/ctr.13246

Scopus ID

2-s2.0-85047877308 (requires institutional sign-in at Scopus site)   26 Citations

Abstract

BACKGROUND: Sorafenib has shown survival benefits in patients with advanced HCC; however, limited data are available on its role in OLT recipients with advanced HCC in the explant.

AIM: Evaluate the role of preemptive sorafenib therapy on HCC recurrence and survival after OLT with advanced HCC on explant pathology.

METHODS: We retrospectively reviewed the outcome after OLT of all HCC recipients with advanced HCC in the explant pathology from 04/2006 to 12/2012 based on preemptive treatment with sorafenib.

RESULTS: During the observation period, 217 HCC recipients underwent OLT; 50 explants revealed advanced HCC. After exclusion of 5 patients who were lost to follow-up, 45 LT recipients were finally included for analysis. Recipients were grouped as sorafenib Gr (N = 25) and nonsorafenib Gr (N = 20). Both recurrence-free survival (RFS) (P = .67) and overall survival were similar between groups (P = .53) on Kaplan-Meier analysis. Additionally, sorafenib use was neither associated with HCC recurrence-free survival (HR 0.74, 95% CI [0.32-1.70]; P = .48) nor overall survival (HR 0.92, 95% CI [0.39-2.15], P = .84) on multivariate Cox proportional hazard model with sorafenib use as time-varying covariates.

CONCLUSION: Preemptive treatment with sorafenib in OLT recipients with high-risk features in explant does not improve HCC recurrence-free or overall survival.

Author List

Satapathy SK, Das K, Kocak M, Helmick RA, Eason JD, Nair SP, Vanatta JM

Author

Ryan Helmick MD Associate Professor in the Surgery department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Antineoplastic Agents
Carcinoma, Hepatocellular
Female
Follow-Up Studies
Graft Rejection
Graft Survival
Humans
Liver Neoplasms
Liver Transplantation
Male
Middle Aged
Neoplasm Recurrence, Local
Preoperative Care
Prognosis
Retrospective Studies
Risk Factors
Survival Rate